💊

Cholinergic Antagonists Overview

Jul 1, 2025

Overview

This lecture covers cholinergic antagonists, focusing on their classification, mechanisms, clinical uses, and major drugs. Side effects and key differences between drug classes are emphasized.

Cholinergic Antagonists Classification

  • Cholinergic antagonists are divided into antimuscarinic agents, ganglionic blockers, and neuromuscular blockers.
  • Each class targets different cholinergic receptors and produces distinct clinical effects.

Antimuscarinic Agents

  • Antimuscarinic drugs block muscarinic receptors, inhibiting muscarinic functions.
  • Atropine acts on the eye (causes mydriasis, cycloplegia), GI tract (reduces motility), heart (increases rate), and glands (dry mouth, skin).
  • Cyclopentolate and Tropicamide are preferred over Atropine for eye exams due to shorter duration.
  • Scopolamine is used for motion sickness and post-operative nausea; it acts mainly on the CNS and lasts up to three days.
  • Ipratropium and Tiotropium are inhaled for COPD, causing bronchodilation and decreased mucus; Tiotropium is long-acting, Ipratropium is short-acting.
  • Antimuscarinics like Tolterodine, Oxybutynin, etc., treat overactive bladder by targeting M3 receptors.
  • Benztropine and Trihexyphenidyl treat Parkinson-like disorders by suppressing central cholinergic activity.
  • Common adverse effects remembered as "ABCDS": agitation, blurred vision, constipation/confusion, dry mouth, stasis of urine/sweating.

Ganglionic Blockers

  • Nicotine is a ganglionic blocker, acting as a functional antagonist by stimulating then blocking nicotinic receptors in autonomic ganglia.
  • Nicotine affects both sympathetic and parasympathetic systems, increasing neurotransmitter release, BP, HR, and GI motility.
  • High doses can cause CNS depression, respiratory paralysis, and addiction; limited clinical use except smoking cessation.

Neuromuscular Blockers

  • Neuromuscular blockers inhibit cholinergic transmission at the neuromuscular junction, preventing muscle contraction.
  • Nondepolarizing agents (e.g., Cisatracurium, Rocuronium) are competitive antagonists; used for surgical muscle relaxation and intubation.
  • Onset is rapid; muscles paralyzed in order: face, limbs, then diaphragm; recovery is the reverse.
  • Atracurium can cause histamine release and seizures; Cisatracurium is safer in organ failure patients.
  • Vecuronium and Rocuronium are liver-metabolized; Pancuronium excreted in urine and can raise HR.
  • Depolarizing agent Succinylcholine mimics acetylcholine, causing persistent depolarization and paralysis (used for rapid intubation).
  • Succinylcholine can cause adverse effects like prolonged apnea (in pseudocholinesterase deficiency), hyperkalemia, and malignant hyperthermia.

Key Terms & Definitions

  • Antimuscarinic agents — Drugs that block muscarinic acetylcholine receptors.
  • Ganglionic blockers — Agents that block transmission in autonomic ganglia.
  • Neuromuscular blockers — Drugs that block acetylcholine at skeletal muscle junctions.
  • Nondepolarizing agents — Competitive antagonists at nicotinic receptors, prevent depolarization.
  • Depolarizing agents — Cause persistent activation of nicotinic receptors, leading to paralysis.
  • Mydriasis — Pupil dilation.
  • Cycloplegia — Inability to focus visually.

Action Items / Next Steps

  • Review the adverse effects mnemonic "ABCDS."
  • Watch a brief video on action potential for membrane depolarization review (if needed).
  • Study clinical uses and contraindications for key drugs mentioned.